FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3087133080> ?p ?o ?g. }

• W3087133080 endingPage "76" @default.
• W3087133080 startingPage "57" @default.
• W3087133080 abstract "Causal associations between hereditary and acquired dysregulation of ribosome biogenesis (RiBi) and an increased risk of cancer have been established. However, the mechanisms underlying these associations are only beginning to be explored. Various types of RiBi dysregulation have been linked with alterations in protein synthesis and proteostasis, metabolic processes, redox homeostasis, genome stability, and transcription. Understanding how these alterations contribute to cancer pathogenesis is of great interest as it may reveal targetable cancer vulnerabilities. Impairment of RiBi redirects the nascent preribosomal RNA complex containing ribosomal protein L5 (RPL5), RPL11, and 5S rRNA from RiBi to bind the human homolog of mouse double minute 2 (HDM2) and thereby block HDM2-mediated ubiquitination and degradation of the tumor suppressor p53. This signaling pathway was recently named the impaired ribosome biogenesis checkpoint (IRBC). Animal studies suggest that IRBC signaling acts as a barrier to tumorigenesis by triggering apoptosis or senescence and by preventing DNA damage and genome instability. Recent evidence for the positive selection of specific RPL5 and RPL11 gene mutations in human tumors with wt TP53 further strengthens the role this pathway plays in tumor suppression. CX-5461, the first direct and selective inhibitor of RNA polymerase I, limits tumorigenesis by activating the IRBC. By inhibiting rDNA transcription, CX-5461 triggers rDNA replication stress, thereby explaining synthetic lethal interactions in cancers harboring genetic defects in homologous recombination (HR) or nonhomologous end joining (NHEJ) DNA repair pathways. Ribosome biogenesis (RiBi) is one of the most complex and energy demanding processes in human cells, critical for cell growth and proliferation. Strong causal links between inherited and acquired impairment in RiBi with cancer pathogenesis are emerging, pointing to RiBi as an attractive therapeutic target for cancer. Here, we will highlight new knowledge about causes of excessive or impaired RiBi and the impact of these changes on protein synthesis. We will also discuss how new knowledge about secondary consequences of dysregulated RiBi and protein synthesis, including proteotoxic stress, metabolic alterations, adaptive transcriptional and translational programs, and the impaired ribosome biogenesis checkpoint (IRBC) provide a foundation for the development of new anticancer therapies. Ribosome biogenesis (RiBi) is one of the most complex and energy demanding processes in human cells, critical for cell growth and proliferation. Strong causal links between inherited and acquired impairment in RiBi with cancer pathogenesis are emerging, pointing to RiBi as an attractive therapeutic target for cancer. Here, we will highlight new knowledge about causes of excessive or impaired RiBi and the impact of these changes on protein synthesis. We will also discuss how new knowledge about secondary consequences of dysregulated RiBi and protein synthesis, including proteotoxic stress, metabolic alterations, adaptive transcriptional and translational programs, and the impaired ribosome biogenesis checkpoint (IRBC) provide a foundation for the development of new anticancer therapies." @default.
• W3087133080 created "2020-09-25" @default.
• W3087133080 creator A5000024721 @default.
• W3087133080 creator A5017514539 @default.
• W3087133080 creator A5053081343 @default.
• W3087133080 creator A5079404223 @default.
• W3087133080 creator A5090729430 @default.
• W3087133080 date "2021-01-01" @default.
• W3087133080 modified "2023-10-15" @default.
• W3087133080 title "Dysregulated Ribosome Biogenesis Reveals Therapeutic Liabilities in Cancer" @default.
• W3087133080 cites W1589900034 @default.
• W3087133080 cites W1832085010 @default.
• W3087133080 cites W1898921036 @default.
• W3087133080 cites W1963434741 @default.
• W3087133080 cites W1963566766 @default.
• W3087133080 cites W1965244636 @default.
• W3087133080 cites W1971467793 @default.
• W3087133080 cites W1973568206 @default.
• W3087133080 cites W1976485719 @default.
• W3087133080 cites W1980396381 @default.
• W3087133080 cites W1985821091 @default.
• W3087133080 cites W2006872995 @default.
• W3087133080 cites W2021709122 @default.
• W3087133080 cites W2022314059 @default.
• W3087133080 cites W2048642489 @default.
• W3087133080 cites W2049776490 @default.
• W3087133080 cites W2053586237 @default.
• W3087133080 cites W2055347597 @default.
• W3087133080 cites W2064254630 @default.
• W3087133080 cites W2069501602 @default.
• W3087133080 cites W2082026266 @default.
• W3087133080 cites W2092594973 @default.
• W3087133080 cites W2103666721 @default.
• W3087133080 cites W2105515478 @default.
• W3087133080 cites W2117211763 @default.
• W3087133080 cites W2126393044 @default.
• W3087133080 cites W2127787655 @default.
• W3087133080 cites W2129104457 @default.
• W3087133080 cites W2141455745 @default.
• W3087133080 cites W2165860917 @default.
• W3087133080 cites W2171797494 @default.
• W3087133080 cites W2202553770 @default.
• W3087133080 cites W2220539891 @default.
• W3087133080 cites W2264001446 @default.
• W3087133080 cites W2413047328 @default.
• W3087133080 cites W2470218763 @default.
• W3087133080 cites W2477532021 @default.
• W3087133080 cites W2491065882 @default.
• W3087133080 cites W2511774689 @default.
• W3087133080 cites W2518899399 @default.
• W3087133080 cites W2520077896 @default.
• W3087133080 cites W2558487294 @default.
• W3087133080 cites W2583421453 @default.
• W3087133080 cites W2587610309 @default.
• W3087133080 cites W2588267243 @default.
• W3087133080 cites W2591905283 @default.
• W3087133080 cites W2592715362 @default.
• W3087133080 cites W2593857065 @default.
• W3087133080 cites W2750745925 @default.
• W3087133080 cites W2765462681 @default.
• W3087133080 cites W2765597781 @default.
• W3087133080 cites W2772508026 @default.
• W3087133080 cites W2773619385 @default.
• W3087133080 cites W2792200327 @default.
• W3087133080 cites W2793508531 @default.
• W3087133080 cites W2793800931 @default.
• W3087133080 cites W2797752654 @default.
• W3087133080 cites W2809573934 @default.
• W3087133080 cites W2884910505 @default.
• W3087133080 cites W2886956635 @default.
• W3087133080 cites W2896328850 @default.
• W3087133080 cites W2897322482 @default.
• W3087133080 cites W2902019779 @default.
• W3087133080 cites W2903155579 @default.
• W3087133080 cites W2910848742 @default.
• W3087133080 cites W2912949690 @default.
• W3087133080 cites W2920627390 @default.
• W3087133080 cites W2922484113 @default.
• W3087133080 cites W2944819910 @default.
• W3087133080 cites W2945629440 @default.
• W3087133080 cites W2949343582 @default.
• W3087133080 cites W2949766441 @default.
• W3087133080 cites W2957689718 @default.
• W3087133080 cites W2960777742 @default.
• W3087133080 cites W2962961054 @default.
• W3087133080 cites W2966070481 @default.
• W3087133080 cites W2967821535 @default.
• W3087133080 cites W2973384337 @default.
• W3087133080 cites W2994162014 @default.
• W3087133080 cites W3002480029 @default.
• W3087133080 cites W3003239114 @default.
• W3087133080 cites W3004434748 @default.
• W3087133080 cites W3006876963 @default.
• W3087133080 cites W3008397035 @default.
• W3087133080 cites W3030498015 @default.
• W3087133080 cites W3030525997 @default.
• W3087133080 doi "https://doi.org/10.1016/j.trecan.2020.08.003" @default.
• W3087133080 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32948502" @default.

• next